Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 30.95
(0.0%)
TWD 30.95
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 807.86 Million TWD | -9.88% |
| 2022 | 893.49 Million TWD | -16.41% |
| 2021 | 1.06 Billion TWD | 6.94% |
| 2020 | 999.55 Million TWD | -8.01% |
| 2019 | 1.08 Billion TWD | 15.02% |
| 2018 | 944.67 Million TWD | 8.18% |
| 2017 | 873.28 Million TWD | -6.31% |
| 2016 | 932.07 Million TWD | 1.95% |
| 2015 | 914.25 Million TWD | -2.67% |
| 2014 | 939.32 Million TWD | 17.16% |
| 2013 | 801.77 Million TWD | 23.34% |
| 2012 | 650.07 Million TWD | 3.0% |
| 2011 | 631.15 Million TWD | 5.75% |
| 2010 | 596.82 Million TWD | 1.33% |
| 2009 | 588.98 Million TWD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 200.46 Million TWD | -10.32% |
| 2024 Q1 | 245.14 Million TWD | 43.1% |
| 2023 FY | 805.18 Million TWD | -9.88% |
| 2023 Q1 | 199.48 Million TWD | -31.65% |
| 2023 Q2 | 212.96 Million TWD | 6.75% |
| 2023 Q3 | 219.12 Million TWD | 2.89% |
| 2023 Q4 | 171.31 Million TWD | -21.82% |
| 2022 Q3 | 203.11 Million TWD | 2.29% |
| 2022 Q1 | 199.96 Million TWD | -20.34% |
| 2022 FY | 893.49 Million TWD | -16.41% |
| 2022 Q4 | 291.86 Million TWD | 43.69% |
| 2022 Q2 | 198.55 Million TWD | -0.7% |
| 2021 Q4 | 251.03 Million TWD | -32.73% |
| 2021 Q3 | 373.16 Million TWD | 65.94% |
| 2021 FY | 1.06 Billion TWD | 6.94% |
| 2021 Q1 | 219.85 Million TWD | -13.94% |
| 2021 Q2 | 224.88 Million TWD | 2.29% |
| 2020 Q4 | 255.45 Million TWD | -0.79% |
| 2020 Q1 | 234.12 Million TWD | -18.17% |
| 2020 Q2 | 252.47 Million TWD | 7.84% |
| 2020 FY | 999.55 Million TWD | -8.01% |
| 2020 Q3 | 257.5 Million TWD | 1.99% |
| 2019 Q4 | 286.11 Million TWD | 1.54% |
| 2019 Q3 | 281.77 Million TWD | -0.62% |
| 2019 FY | 1.08 Billion TWD | 15.02% |
| 2019 Q1 | 235.18 Million TWD | -12.56% |
| 2019 Q2 | 283.51 Million TWD | 20.55% |
| 2018 FY | 944.67 Million TWD | 8.18% |
| 2018 Q2 | 227.88 Million TWD | 7.59% |
| 2018 Q1 | 211.81 Million TWD | -6.04% |
| 2018 Q4 | 268.97 Million TWD | 13.97% |
| 2018 Q3 | 236 Million TWD | 3.56% |
| 2017 Q1 | 213.62 Million TWD | -11.25% |
| 2017 Q4 | 225.42 Million TWD | 3.29% |
| 2017 Q3 | 218.24 Million TWD | 1.04% |
| 2017 FY | 873.28 Million TWD | -6.31% |
| 2017 Q2 | 215.99 Million TWD | 1.11% |
| 2016 Q3 | 230.42 Million TWD | -2.34% |
| 2016 FY | 932.07 Million TWD | 1.95% |
| 2016 Q4 | 240.71 Million TWD | 4.47% |
| 2016 Q2 | 235.94 Million TWD | 4.87% |
| 2016 Q1 | 224.98 Million TWD | -0.12% |
| 2015 FY | 914.25 Million TWD | -2.67% |
| 2015 Q1 | 219.89 Million TWD | -18.1% |
| 2015 Q2 | 227.33 Million TWD | 3.39% |
| 2015 Q4 | 225.24 Million TWD | -6.84% |
| 2015 Q3 | 241.77 Million TWD | 6.35% |
| 2014 Q4 | 268.48 Million TWD | 13.14% |
| 2014 Q2 | 228.26 Million TWD | 11.19% |
| 2014 Q1 | 205.28 Million TWD | -14.25% |
| 2014 FY | 939.32 Million TWD | 17.16% |
| 2014 Q3 | 237.29 Million TWD | 3.95% |
| 2013 Q1 | 183.66 Million TWD | 5.29% |
| 2013 Q3 | 199.08 Million TWD | 10.84% |
| 2013 Q4 | 239.4 Million TWD | 20.25% |
| 2013 FY | 801.77 Million TWD | 23.34% |
| 2013 Q2 | 179.61 Million TWD | -2.2% |
| 2012 Q4 | 174.44 Million TWD | 6.26% |
| 2012 Q3 | 164.17 Million TWD | 0.83% |
| 2012 FY | 650.07 Million TWD | 3.0% |
| 2012 Q2 | 162.82 Million TWD | 10.46% |
| 2012 Q1 | 147.4 Million TWD | -10.95% |
| 2011 Q2 | 150.21 Million TWD | -1.47% |
| 2011 Q1 | 152.45 Million TWD | -1.45% |
| 2011 Q3 | 162.96 Million TWD | 8.49% |
| 2011 Q4 | 165.52 Million TWD | 1.57% |
| 2011 FY | 631.15 Million TWD | 5.75% |
| 2010 Q3 | 152.57 Million TWD | 1.62% |
| 2010 FY | 596.82 Million TWD | 1.33% |
| 2010 Q1 | 139.4 Million TWD | 0.0% |
| 2010 Q4 | 154.7 Million TWD | 1.39% |
| 2010 Q2 | 150.14 Million TWD | 7.7% |
| 2009 FY | 588.98 Million TWD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Apex Biotechnology Corp. | 389.4 Million TWD | -107.465% |
| Panion & Bf Biotech Inc. | 817.56 Million TWD | 1.186% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 437.58 Million TWD | -84.621% |
| GenMont Biotech Incorporation | 204.2 Million TWD | -295.619% |
| Abnova (Taiwan) Corporation | 126.72 Million TWD | -537.518% |
| Adimmune Corporation | 1.13 Billion TWD | 28.739% |
| Tanvex BioPharma, Inc. | 2.16 Billion TWD | 62.606% |
| Polaris Group | -3.06 Million TWD | 26457.879% |
| Energenesis Biomedical CO.,LTD. | 267.06 Million TWD | -202.5% |
| UnicoCell Biomed Co., Ltd. | 17.89 Million TWD | -4413.991% |
| PELL Bio-Med Technology Co. Ltd. | 385.1 Million TWD | -109.778% |